Y. Hadi, Abdulrahman Ibrahim Abu Aqil, Q. Alshammari
{"title":"Radiologist Assistant: Improving Patient Care While Providing Workforce Solutions in Saudi Arabia","authors":"Y. Hadi, Abdulrahman Ibrahim Abu Aqil, Q. Alshammari","doi":"10.51847/qwhtebcfzi","DOIUrl":"https://doi.org/10.51847/qwhtebcfzi","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70832077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolae Dumitru Nicoară, Paula Marian, Alin Ovidiu Petriș, Cristian Delcea, Felicia Manole
{"title":"A Review of the Role of Cognitive-Behavioral Therapy on Anxiety Disorders of Children and Adolescents","authors":"Nicolae Dumitru Nicoară, Paula Marian, Alin Ovidiu Petriș, Cristian Delcea, Felicia Manole","doi":"10.51847/lkulo5pb1t","DOIUrl":"https://doi.org/10.51847/lkulo5pb1t","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135181738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katarzyna Szklener, Karolina Nieoczym, Katarzyna Niedziela, Łukasz Światłowski, Sławomir Mańdziuk
Genetic abnormalities in the anaplastic lymphoma (ALK) kinase gene are present in 3-5% of Non-squamous Cell Lung Cancer (NSCLC) cases. ALK gene rearrangement plays a crucial role in determining the sensitivity of neoplastic cells to small molecule ALK tyrosine kinase inhibitors. However, some patients may develop resistance to ALK inhibitors over time, leading to disease progression. In such cases, it is important to perform genetic testing to identify any emerging mutations that may be responsible for resistance and to select the appropriate subsequent treatment. We provide a case of a 56-year-old patient with advanced NSCLC. The patient achieved an overall progression-free survival of 71 months, which highlights the potential benefits of using a sequence of ALK inhibitors in treating advanced ALK-rearranged lung adenocarcinoma. Overall, this case study highlights the importance of genetic profiling and personalized treatment in managing advanced NSCLC, and it offers hope for improved outcomes in patients
{"title":"Exceptionally Long Survival with Lorlatinib in a Patient with Alk-Rearranged Lung","authors":"Katarzyna Szklener, Karolina Nieoczym, Katarzyna Niedziela, Łukasz Światłowski, Sławomir Mańdziuk","doi":"10.51847/n1yjzejnbd","DOIUrl":"https://doi.org/10.51847/n1yjzejnbd","url":null,"abstract":"Genetic abnormalities in the anaplastic lymphoma (ALK) kinase gene are present in 3-5% of Non-squamous Cell Lung Cancer (NSCLC) cases. ALK gene rearrangement plays a crucial role in determining the sensitivity of neoplastic cells to small molecule ALK tyrosine kinase inhibitors. However, some patients may develop resistance to ALK inhibitors over time, leading to disease progression. In such cases, it is important to perform genetic testing to identify any emerging mutations that may be responsible for resistance and to select the appropriate subsequent treatment. We provide a case of a 56-year-old patient with advanced NSCLC. The patient achieved an overall progression-free survival of 71 months, which highlights the potential benefits of using a sequence of ALK inhibitors in treating advanced ALK-rearranged lung adenocarcinoma. Overall, this case study highlights the importance of genetic profiling and personalized treatment in managing advanced NSCLC, and it offers hope for improved outcomes in patients","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135002033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Wanjari, B. Rathi, Dinesh Santoshrao Wanjari, Rohit Ajit Gokarn
{"title":"Interdisciplinary Perspective of Laghumalini Vasant an Ayurvedic Formulation Towards Therapeutic Potential in Antenatal Care","authors":"A. Wanjari, B. Rathi, Dinesh Santoshrao Wanjari, Rohit Ajit Gokarn","doi":"10.51847/5fppjrfii5","DOIUrl":"https://doi.org/10.51847/5fppjrfii5","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70812902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. M. A. El-Mawgod, A. Agarwal, Bishri Fawzan Almesned, M. M. Alruwaili, Shuruq Alshammari, Rehab Madallah Sulaiman Almatrafi
{"title":"Knowledge, Attitudes, and Practices Associated with Vitamin D Misuse among General Population during COVID-19","authors":"M. M. A. El-Mawgod, A. Agarwal, Bishri Fawzan Almesned, M. M. Alruwaili, Shuruq Alshammari, Rehab Madallah Sulaiman Almatrafi","doi":"10.51847/cmnejaqtlr","DOIUrl":"https://doi.org/10.51847/cmnejaqtlr","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70817521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Q. Alshammari, Awatif Radhy Alshammari, Amjad R. Alyahyawi, Alaa Sharef Alhmshe, Alanoud Saad Alshammari, Mai Fhaid Alshammari, S. Cg, M. Alshammari, M. A. Alghamdi, Asma Saud Alanazi
{"title":"MRI Assessment of Rotator Cuff Tear in Patients with Shoulder Pain","authors":"Q. Alshammari, Awatif Radhy Alshammari, Amjad R. Alyahyawi, Alaa Sharef Alhmshe, Alanoud Saad Alshammari, Mai Fhaid Alshammari, S. Cg, M. Alshammari, M. A. Alghamdi, Asma Saud Alanazi","doi":"10.51847/q4teobtciz","DOIUrl":"https://doi.org/10.51847/q4teobtciz","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"9 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70830803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacokinetics of Amikacin in Eye Media Using Various Drugs","authors":"Markha Khozh-Akhmedovna Bersanova, Lina Magomedovna Batkhieva, Tamar Elbrusovna Baramiya, Daniela Georgievna Birkaya, Elena Vladimirovna Belokobylskaya, Zulmira Temirsoltanovna Saidova","doi":"10.51847/qzs08gqjvc","DOIUrl":"https://doi.org/10.51847/qzs08gqjvc","url":null,"abstract":"","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"8 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70832090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ian Lemuel Sigue Virtucio, J. Punzalan, J. Billones
The COVID-19 pandemic remains to be a global public health crisis due to the emergence of new variants of concern and the scarcity of drug treatments. The cell entry of SARS-CoV-2 requires activation of its spike protein by host proteases TMPRSS2 and CTSL, which triggers membrane fusion and facilitates the endocytic uptake mechanism, respectively. This study employed a structure-based virtual screening technique to identify drugs and natural products that simultaneously target TMPRSS2 and CTSL. Two pharmacophore models were generated from the binding sites of the proteins in complex with their co-crystallized ligands. Both structure-based pharmacophores were used to screen a ligand library composed of 41,775 compounds (10,849 drugs from the ChEMBL database and 30,926 natural products from the NPASS database). A total of 115 compounds (54 drugs and 61 natural products) that fit both TMPRSS2 and CTSL pharmacophore models were identified. The common hits were docked into both proteases to obtain a short list of compounds. Molecular docking filtered 17 compounds (5 drugs and 12 natural products) that have higher binding energy values than the co-crystallized ligands and known inhibitors of both proteins. The top hits were then subjected to ADMET, drug-likeness, and synthetic accessibility filters. Based on docking scores, pharmacokinetics, and drug-likeness, Silibinin was the most promising repurposed drug candidate as a treatment for SARS-CoV-2 infection via dual inhibition of TMPRSS2 and CTSL. Among the natural products, barettin was the best candidate for further development as a novel dual TMPRSS2 and CTSL inhibitor.
{"title":"Virtual Screening for SARS-COV-2 Entry Inhibitors by Dual Targeting of TMPRSS2 and CTSL","authors":"Ian Lemuel Sigue Virtucio, J. Punzalan, J. Billones","doi":"10.51847/6imwqjwvpa","DOIUrl":"https://doi.org/10.51847/6imwqjwvpa","url":null,"abstract":"The COVID-19 pandemic remains to be a global public health crisis due to the emergence of new variants of concern and the scarcity of drug treatments. The cell entry of SARS-CoV-2 requires activation of its spike protein by host proteases TMPRSS2 and CTSL, which triggers membrane fusion and facilitates the endocytic uptake mechanism, respectively. This study employed a structure-based virtual screening technique to identify drugs and natural products that simultaneously target TMPRSS2 and CTSL. Two pharmacophore models were generated from the binding sites of the proteins in complex with their co-crystallized ligands. Both structure-based pharmacophores were used to screen a ligand library composed of 41,775 compounds (10,849 drugs from the ChEMBL database and 30,926 natural products from the NPASS database). A total of 115 compounds (54 drugs and 61 natural products) that fit both TMPRSS2 and CTSL pharmacophore models were identified. The common hits were docked into both proteases to obtain a short list of compounds. Molecular docking filtered 17 compounds (5 drugs and 12 natural products) that have higher binding energy values than the co-crystallized ligands and known inhibitors of both proteins. The top hits were then subjected to ADMET, drug-likeness, and synthetic accessibility filters. Based on docking scores, pharmacokinetics, and drug-likeness, Silibinin was the most promising repurposed drug candidate as a treatment for SARS-CoV-2 infection via dual inhibition of TMPRSS2 and CTSL. Among the natural products, barettin was the best candidate for further development as a novel dual TMPRSS2 and CTSL inhibitor.","PeriodicalId":20012,"journal":{"name":"Pharmacophore","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70813710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：